Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAUH96)

Drug Name

alpha-methylphenylalanine Drug Info

Synonyms

alpha-Methyl-DL-phenylalanine; 1132-26-9; 2-amino-2-methyl-3-phenylpropanoic acid; 2-Amino-2-methyl-3-phenylpropionic acid; alpha-Methylphenylalanine; H--Me-DL-Phe-OH; HYOWVAAEQCNGLE-UHFFFAOYSA-N; alpha-Methyl-DL-phenylalanine, 98%; MFCD00010512; Phenylalanine, alpha-methyl-; 2-amino-2-methyl-3-phenyl-propanoic acid; 2-Methylphenylalanine #; D,L-Phe(alphaMe)-OH; a-methyl-dl-phenylalanine; alpha-me-dl-phenylalanine; Methylphenylalanine, alpha; H-DL-(ME)PHE-OH; dl-alpha-methylphenylalanine; ACMC-1AH59

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 108055
CAS Number: CAS 1132-26-9
TTD Drug ID: DMAUH96

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phenylalanine hydroxylase (PAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sapropterin hydrochloride	DM90TJP	Hyperphenylalaninemia	5C50	Approved	[3]
Pegvaliase	DM6NZ2P	Phenylketonuria	5C50.0	Approved	[4]
Phenylalanine hydroxylase	DMRP3CV	Autoimmune diabetes	5A10	Phase 2	[5]
HepaStem	DM8QGPE	Liver failure	DB99.7	Phase 2	[6]
HMI-102	DM8B85Y	Phenylketonuria	5C50.0	Phase 1/2	[7]
BMN-307	DMY0SKM	Phenylketonuria	5C50.0	Phase 1/2	[8]
fenclonine	DMUBO3E	Discovery agent	N.A.	Investigative	[6]
BMN-168	DM0VMZ4	Phenylketonuria	5C50.0	Investigative	[6]
ALTU-236	DMDLN9S	Genetic disease	8E02	Investigative	[6]
BH4	DM4XMZW	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phenylalanine hydroxylase (PAH)	TTGSVH2	PH4H_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5093).
2	Alpha-methylphenylalanine, a new inducer of chronic hyperphenylalaninemia in sucling rats. Science. 1976 Jun 4;192(4243):1007-8.
3	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
4	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227.
5	Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
7	Clinical pipeline report, company report or official report of Homology Medicines
8	ClinicalTrials.gov (NCT04480567) A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects With Phenylketonuria. U.S.National Institutes of Health.
9	Company report of BioMarin